Skip to main content
. 2020 Feb 24;15(2):e0229260. doi: 10.1371/journal.pone.0229260

Table 3. Demographic parameters of the glaucoma cohort.

N 52
Age (years) 48.0±18.8
Gender (male/female) 36 (69.2%) / 16 (30.8%)
Pathogenic virus RV 11 (21.2%) (AI: 24.31±45.71)
CMV 32 (61.5%) (AI: 30.07±81.57)
HSV 5 (9.6%) (AI: 5.24±2.32)
VZV 3 (5.8%) (AI:3.15±0.13)
MV 1 (1.9%) (AI: 2.99)
Before AC stab incision Side (right/left) 31 (59.6%) / 21 (40.4%)
Involvement (unilateral/bilateral) 50 (96.2%) / 2 (3.8%)
Course of disease (acute/chronic) 38 (73.1%) / 14 (26.9%)
Previous keratitis 9 (17.3%)
Visual acuity (logMAR) 0.16±0.32
IOP 29.79±10.66 mmHg
Local therapy 2.08±0.81
Systemic glaucoma therapy (acetazolamid) 18 (34.6%)
Steroid therapy (local) 37 (71.2%)
Clinical findings Conjunctival redness 28 (53.8%)
Corneal edema 1 (1.9%)
Keratic precipitates 42 (80.8%)
Character of precipitates (granulomatous/fine/pigmented /not documented/nothing) 8 (15.4%) / 22 (42.3%) / 7 (13.5%) / 6 (11.5%) / 9 (17.3%)
Location of precipitates (Arlt´s triangle/diffuse scattered/endotheliitis/not documented) 8 (15.4%) / 27 (51.9%) / 2 (3.8%) / 15 (28.8%)
Cells in anterior chamber 18 (34.6%)
Hypopyon 0 (0%)
Fibrin 4 (7.7%)
Iris Synechiae 2 (3.8%)
Irisatrophy 6 (11.5%)
Heterochromia 8 (15.4%)
Lens (corticonuclear cataract or subcapsular posterior cataract/ pseudophacic/ clear lens 14 (26.9%) /11 (21.2%) / 27 (51.9%)
Vitreous Haze (0/+1/+2/+3) 47 (90.4%) / 4 (7.7%) / 1 (1.9%) / 0 (0%)
Retinal infiltrates 0 (0%)
Macula edema 0 (0%)
Recurrence recurrence (no /yes /not documented) 13 (25.1%) / 37 (71.1%) / 2 (3.8%)

AC = anterior chamber, CMV = cytomegalovirus, HSV = herpes simplex virus, MV = multiple virus, RV = rubella, VZV = varicella-zoster virus, IOP = intraocular pressure